Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $29.20.
Several brokerages have commented on KURA. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday, August 9th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th.
View Our Latest Report on KURA
Institutional Investors Weigh In On Kura Oncology
Kura Oncology Stock Performance
NASDAQ:KURA opened at $17.37 on Wednesday. The firm’s fifty day moving average price is $19.45 and its 200 day moving average price is $20.15. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -8.00 and a beta of 0.84.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.53) earnings per share. On average, sell-side analysts expect that Kura Oncology will post -2.45 EPS for the current year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Kura Oncology
- Overbought Stocks Explained: Should You Trade Them?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Choose Top Rated Stocks
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Profitably Trade Stocks at 52-Week Highs
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.